Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Ensysce Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Ensysce Biosciences, Inc.

ENSC ENSCW

Ensysce Biosciences, Inc.

About Ensysce Biosciences, Inc.

Ensysce Biosciences is a clinical-stage pharmaceutical company developing innovative opioid and pain management solutions. Its proprietary TAAP and MPAR platforms create abuse-resistant and overdose-protective prodrugs, aiming to reduce misuse, overdose, and addiction. The company focuses on safer opioid products for pain relief and opioid use disorder, targeting markets with high societal impact, leveraging novel molecular delivery technologies to improve safety and efficacy.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Ensysce Biosciences, Inc.

1
1
Ensysce Biosciences, Inc. Ensysce Biosciences Reports $3.6 Million Net Loss in Q1 2026, Revenue Declines

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Ensysce Biosciences, Inc. Ensysce Biosciences Reports $10.2 Million Net Loss for 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Ensysce Biosciences, Inc. Ensysce Biosciences Reports Significant Revenue Decline and Increased Losses in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Ensysce Biosciences, Inc. Ensysce Biosciences Reports Revenue Growth Driven by Federal Grants in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Ensysce Biosciences, Inc. Ensysce Biosciences Reports Q1 2025 Financial Results with Improved Net Loss and Increased Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Ensysce Biosciences, Inc. Ensysce Biosciences Reports $7.99 Million Net Loss and Increased Revenue from Grants in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Ensysce Biosciences, Inc. Ensysce Biosciences Reports Improved Financials, Reduced Losses in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments